| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
The primary molecular target of Blumeatin B is xanthine oxidase (XO), a key enzyme involved in the production of uric acid. By inhibiting XO, Blumeatin B may help reduce uric acid levels, making it a potential tool for hyperuricemia research. It also exhibits antioxidant activity through DPPH radical scavenging and has potent anticancer effects.
|
|---|---|
| ln Vitro |
In vitro, Blumeatin B shows xanthine oxidase (XO) inhibitory activity. It delivers 27.7% higher DPPH radical scavenging than quercetin (IC₅₀ 6.27 vs. 8.67 µg/mL). It has potent anticancer effects and exhibits hepatoprotective effects by inhibiting the increase of serum alanine aminotransferase and liver triglycerides while increasing serum triglycerides, beta-lipoprotein, and liver glycogen content.
|
| ln Vivo |
In vivo, Blumeatin B exhibits hepatoprotective effects by inhibiting the increase of serum alanine aminotransferase and liver triglycerides while increasing serum triglycerides, beta-lipoprotein, and liver glycogen content in carbon tetrachloride-intoxicated rats. Its xanthine oxidase inhibitory activity suggests potential for treating hyperuricemia and gout. Its anticancer effects suggest potential for cancer research.
|
| Enzyme Assay |
Typical in vitro assays for Blumeatin B include xanthine oxidase inhibition assays, where the enzyme is incubated with xanthine substrate and various concentrations of the compound, and uric acid production is measured at 290 nm. DPPH radical scavenging assays are performed by incubating the compound with DPPH radical solution and measuring absorbance at 517 nm. Cytotoxicity assays are performed using cancer cell lines treated with the compound for 48-72 hours, and cell viability is assessed by MTT assay.
|
| Cell Assay |
Cellular assays for Blumeatin B typically involve treating cancer cell lines or hepatocytes with the compound at concentrations ranging from 1-100 µM for 24-72 hours. Cell viability is assessed by MTT assay. Xanthine oxidase activity can be measured in cell lysates. Antioxidant activity is assessed by measuring ROS levels using fluorescent probes. Hepatoprotective effects are assessed by measuring liver enzyme levels in hepatocyte cultures.
|
| Animal Protocol |
In vivo animal experiments for Blumeatin B typically involve carbon tetrachloride-intoxicated rats to assess hepatoprotective effects. Rats are administered the compound orally or intraperitoneally at doses ranging from 10-50 mg/kg. Serum alanine aminotransferase, liver triglycerides, serum triglycerides, beta-lipoprotein, and liver glycogen content are measured. For xanthine oxidase studies, hyperuricemic animal models are used, and serum uric acid levels are measured.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Blumeatin B are limited. As a flavonoid with a molecular weight of 332.30 g/mol, it would be expected to have moderate oral bioavailability. Flavonoids are typically absorbed and metabolized by conjugation reactions. However, detailed ADME parameters are not available in the consulted sources.
|
| Toxicity/Toxicokinetics |
Toxicological data for Blumeatin B are limited. As a natural flavonoid, it is generally considered to have low toxicity. The compound's antioxidant properties suggest it may have protective effects. However, comprehensive toxicological studies have not been reported. Standard laboratory safety precautions should be followed when handling the compound.
|
| References | |
| Additional Infomation |
(2R,3R)-3,5-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-methoxy-2,3-dihydrochromene-4-one has been reported in irises (Iris potaninii), Blumea fistulosa, and other organisms with available data.
Blumeatin B (3,3',5-Trihydroxy-4',7-dimethoxyflavanone) is a flavonoid with xanthine oxidase inhibitory activity, DPPH radical scavenging activity (IC₅₀ 6.27 µg/mL), hepatoprotective effects, and potent anticancer effects. It is a research compound for studying hyperuricemia, gout, oxidative stress, liver protection, and cancer. It is not approved for any clinical indication. |
| Molecular Formula |
C17H16O7
|
|---|---|
| Molecular Weight |
332.30
|
| Exact Mass |
332.089
|
| CAS # |
79995-67-8
|
| PubChem CID |
157600
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
627.8±55.0 °C at 760 mmHg
|
| Flash Point |
234.4±25.0 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.645
|
| LogP |
2.3
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
24
|
| Complexity |
456
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O=C1[C@H](O)[C@@H](C2C=CC(OC)=C(O)C=2)OC2C=C(C=C(C1=2)O)OC
|
| InChi Key |
SVPNMFZMHPLGRR-DLBZAZTESA-N
|
| InChi Code |
InChI=1S/C17H16O7/c1-22-9-6-11(19)14-13(7-9)24-17(16(21)15(14)20)8-3-4-12(23-2)10(18)5-8/h3-7,16-19,21H,1-2H3/t16-,17+/m0/s1
|
| Chemical Name |
(2R,3R)-3,5-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-methoxy-2,3-dihydrochromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0093 mL | 15.0466 mL | 30.0933 mL | |
| 5 mM | 0.6019 mL | 3.0093 mL | 6.0187 mL | |
| 10 mM | 0.3009 mL | 1.5047 mL | 3.0093 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
